Multidrug-Resistant TB Set to Increase Through 2040

This article originally appeared here.
Share this content:
Multidrug-Resistant TB Set to Increase Through 2040
Multidrug-Resistant TB Set to Increase Through 2040

THURSDAY, May 11, 2017 (HealthDay News) -- Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are expected to increase through 2040, according to a study published online May 9 in The Lancet Infectious Diseases.

Aditya Sharma, M.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues calibrated a compartmental model to data from drug resistance surveys and World Health Organization tuberculosis reports to forecast estimates of incident MDR and XDR tuberculosis in India, the Philippines, Russia, and South Africa from 2000 to 2040.

The researchers found that the percentage of MDR tuberculosis among incident cases of tuberculosis was forecast to increase, reaching 12.4, 8.9, 32.5, and 5.7 percent in India, the Philippines, Russia, and South Africa, respectively, in 2040. The percentage of XDR tuberculosis among incident MDR tuberculosis was also predicted to increase, reaching 8.9, 9.0, 9.0, and 8.5 percent in India, the Philippines, Russia, and South Africa, respectively, in 2040. During 2000 to 2040, acquired drug resistance was expected to cause less than 30 percent of incident MDR tuberculosis. In 2000, acquired drug resistance caused 80 percent of incident tuberculosis; by 2040, this is expected to decline to less than 50 percent.

"Additional control efforts beyond improving acquired drug resistance rates are needed to stop the spread of MDR and XDR tuberculosis in countries with a high burden of MDR tuberculosis," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Cost-Effectiveness of PCSK9 Inhibitors Called Into Question

Researchers say price would have to be between $4,000 and $5,000 per year to be cost-effective

Vitamin B6, B12 Supplements May Up Risk of Lung Cancer in Men

Vitamin B6, B12 Supplements May Up Risk of ...

Increased odds only seemed to affect men or male smokers

Tablet Use Encourages Patients to Explore Diabetes Risk

Tablet Use Encourages Patients to Explore Diabetes Risk

Replacing magazines with tablets can help patients learn about diabetes risk, take preventive action

is free, fast, and customized just for you!

Already a member?

Sign In Now »